Tuesday Dec 3
Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months
Rxi Pharmaceuticals is an RNAi biotechnology company that is developing RNAi drug candidates for unmet medical needs.
Mon Dec 02, 2013
Alnylam Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference
Great. So, it's Alethia Young here, one of the analysts at Deutsche Bank. Very happy to have Alnylam today, Laurence Reid, who is SVP and Chief Business Officer.
Sun Dec 01, 2013
Recent Study: Alnylam Pharmaceuticals, Inc. (ALNY) - Pharmaceuticals...
The company is primarily involved in its Alnylam 5x15 program for developing RNAi based therapeutics targeted against genetically defined diseases.
Wed Nov 27, 2013
Buy Isis On Antisense, Collaborations And Upcoming Catalysts
Isis Pharmaceuticals is a promising company, with expanded operations and diversified pipeline.
Alnylam gets $7M milestone from Genzyme for rare disease drug
Alnylam Pharmaceuticals has received a $7 million milestone payment from partner Genzyme Corp. for its most advanced drug for a rare, inherited heart disease, following recently-released results from a mid-stage trial.
Mon Nov 25, 2013
Alnylam to Webcast Presentation at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 7:50 a.m. ET at the Four Seasons Hotel in Boston.
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II...
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran , an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis - Recent Phase II Clinical Results Showed up to 96% Knockdown of TTR with Activity toward Both Wild-Type and Mutant TTR - - Alnylam Recently Initiated APOLLO Phase ... (more)
Sun Nov 17, 2013
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting
Alnylam Pharmaceuticals announced today that it has presented new pre-clinical data from two RNAi therapeutic programs for cardiovascular disease, including: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 for the treatment of genetic forms of mixed ... (more)
Tue Nov 12, 2013
RXi Pharmaceuticals' Valuation Moves From Product To Platform
The RNAi space has been experiencing a robust recovery from its early failures as recent clinical trials have demonstrated its viability.
Mon Nov 11, 2013
Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an ...
Alnylam Receives Fast Track Designation for Patisiran , an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis )-- Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to patisiran for the treatment of ... (more)
Sun Nov 10, 2013
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran
Tekmira Pharmaceuticals Corporation , a leading developer of RNA interference therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented positive results from its Phase II clinical trial with patisiran , an RNAi therapeutic targeting transthyretin for the treatment of TTR-mediated amyloidosis , which is enabled by Tekmira's lipid ... (more)
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an...
Alnylam Reports Positive Phase II Data for Patisiran , an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis , and Initiates Phase III Trial - New Results in ATTR Patients Show up to 96% Knockdown of TTR with Activity toward Both Wild-Type and Mutant TTR - - Company Initiates APOLLO Phase III Trial, with Study ... (more)
Sat Nov 09, 2013
Alnylam Pharmaceuticals Given Neutral Rating at Zacks
's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Friday, Stock Ratings News reports.
Thu Nov 07, 2013
Alnylam Pharmaceuticals to Present New Pre-clinical Data on Multiple...
Alnylam Pharmaceuticals to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it will present new pre-clinical data from its ALN-AT3, ALN-CC5, and ALN-TMP programs at the 55th Annual ... (more)